Provided by Tiger Trade Technology Pte. Ltd.

Zevra Therapeutics

11.73
-0.1390-1.17%
Volume:524.86K
Turnover:6.16M
Market Cap:693.48M
PE:12.22
High:12.01
Open:11.98
Low:11.45
Close:11.87
52wk High:15.04
52wk Low:7.16
Shares:59.11M
Float Shares:53.86M
Volume Ratio:0.63
T/O Rate:0.97%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.9602
EPS(LYR):1.35
ROE:34.80%
ROA:8.74%
PB:3.19
PE(LYR):8.69

Loading ...

Zevra Therapeutics Grants New Hires Options for 92,200 Shares Under Inducement Plan

Reuters
·
Aug 22

Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 22

Zevra Therapeutics Price Target Maintained with a $26.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 20

Zevra Therapeutics Chief Legal & Compliance Rahsaan Thompson Sells 42,666 Shares for $474,781.44

Reuters
·
Aug 18

Zevra Therapeutics Director Corey Michael Watton Disposes of 12,300 Common Shares for $138,377.46

Reuters
·
Aug 13

Zevra Therapeutics Price Target Cut to $23.00/Share from $24.00 by Guggenheim

Dow Jones
·
Aug 08

Zevra Therapeutics (ZVRA) Receives a Buy from Cantor Fitzgerald

TIPRANKS
·
Aug 07

Ardelyx Says Q2 Product Revenue at Record High but Ibsrela Revenue Below Expectations

Reuters
·
Aug 07

BioMarin Q2 Revenue Beats Estimates; Raises 2026 Outlook

Reuters
·
Aug 07

Roth MKM Sticks to Their Buy Rating for Zevra Therapeutics (ZVRA)

TIPRANKS
·
Aug 07

Zevra Therapeutics is Maintained at Market Outperform by Citizens

Dow Jones
·
Aug 06

Zevra Therapeutics price target raised to $28 from $25 at Citizens

TIPRANKS
·
Aug 06

Zevra Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Zevra Therapeutics reports Q2 EPS 14c, consensus 16c

TIPRANKS
·
Aug 06

Zevra Therapeutics Q2 Revenue Rises 53% on Miplyffa Sales

Reuters
·
Aug 06

Zevra Net Income Drops 88.29% to $8.8 Million in Q2 FY26; Revenue Rises 53% to $39.7 Million

Reuters
·
Aug 06

Zevra Therapeutics Q2 EPS $0.14 Beats $0.11 Estimate, Sales $39.663M Beat $33.881M Estimate

Benzinga Earnings
·
Aug 06

Zevra Therapeutics: Expects to Continue Engagement with the U.S. FDA in the H2 2026 to Explore Pathways to Accelerate Clinical Development

THOMSON REUTERS
·
Aug 06

Zevra Therapeutics to Present at Canaccord Genuity Annual Growth Conference

Reuters
·
Aug 04

Zevra Therapeutics Inc Expected to Post Earnings of 11 Cents a Share - Earnings Preview

Reuters
·
Aug 04